Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

Annals of Oncology

Volumn 20, Issue 3, 2009, Pages 449-453

  Roy, Vivek ^a   Laplant, B R ^b   Gross, G G ^c   Bane, C L ^d   Palmieri, F M ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MeritCare Roger Maris Cancer Center   (United States)

^d The Sapphire Group   (United States)

Author keywords

Breast cancer; Chemotherapy; Gemcitabine; Nab paclitaxel

Indexed keywords

GEMCITABINE; NANOPARTICLE; NANOPARTICLE ALBUMIN BOUND PACLITAXEL; PACLITAXEL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; METASTASIS; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL;

EID: 61649107667     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn661     Document Type: Article

References (21)

1. Sparreboom A, van Zuylen L, Brouwer E et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications. Cancer Res 1999; 59(7): 1454-1457.
2. John TA, Vogel SM, Tiruppathi C et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003; 284(1): L187-L96.
3. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23(31): 7794-7803.
4. Blum J, Savin M, Edelman G et al. Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel. J Clin Oncol 2004; Vol 22: 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) (No 14S, July 15 Suppl): (Abstr 543).
5. Gradishar W, Krasnojon D, Cheporov S et al. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3W solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). Breast Cancer Res Treat 2006; 100 (Suppl 1): (Abstr 46).
6. Kroep JR, Giaccone G, Voorn DA et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-smallcell lung cancer. J Clin Oncol 1999; 17(7): 2190-2197.
7. Zupi G, Scarsella M, D'Angelo C et al. Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. Cancer Biol Ther 2005; 4(8): 866-871.
8. O'Shaughnessy J, Nag S, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Interim results of a global phase III study. Proc Am Soc Clin Oncol 2003; 22: (Abstr 25).
9. Albain K, Nag S, Calderillo-Ruiz G et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 2004; 22(14S): 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) (Abstr 510).
10. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20(12): 2812-23.
11. Moinpour C, Wu J, Donaldson G et al. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study. Proc Am Soc Clin Oncol 2004; 22(14S): (Abstr 621).
12. Perez EA, Vogel CL, Irwin DH et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19(22): 4216-4223.
13. Seidman AD, Berry D, Cirrincione C et al. Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol 2004; 22(14S): (Abstr 512).
14. Blum JL, Savin M, Edelman G et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007; 7(11): 850-856.
15. Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12(4): 1317-1324.
16. Bouras T, Lisanti MP, Pestell RG. Caveolin-1 in breast cancer. Cancer Biol Ther 2004; 3(10): 931-941.
17. Yang G, Truong LD, Timme TL et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998; 4(8): 1873-1880.
18. Pinilla SM, Honrado E, Hardisson D et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006; 99(1): 85-90.
19. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007; 8(3): 185-194.
20. Pelkmans L, Puntener D, Helenius A. Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science 2002; 296(5567): 535-539.
21. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666-2676.